Circassia pulls plug on AZ agreement
Circassia will shed its debt to AstraZeneca under the move
Read More
Tag: Tudorza
Circassia takes on full US rights to AZ’ Tudorza
Circassia Pharmaceuticals is exercising an option to acquire the full US commercial rights to AstraZeneca’s Tudorza.
Read More
AZ’ Tudorza hits study goals in COPD patients with CV risk factors
AstraZeneca says top-line results from a post-marketing study show that Tudorza Pressair is effective in reducing chronic obstructive pulmonary disease (COPD) exacerbations in patients with cardiovascular issues.
Read More
Second US rejection for AZ’ potassium binder
AstraZeneca’s hyperkalaemia treatment ZS-9 has suffered another setback on the path to US approval having been rejected by regulators for the second time. The drug giant also unveiled a US-based partnership with Circassia for development and commercialisation of COPD drugs Turdoza and Duaklir.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
